期刊文献+

小细胞肺癌维持治疗的研究进展 被引量:10

Research Progression of Maintenance Therapy in Small Cell Lung Cancer
下载PDF
导出
摘要 肺癌是世界上最常见的恶性肿瘤之一,其中小细胞肺癌发生率约15%。小细胞肺癌对一线化疗高度敏感,但多数患者在一线治疗缓解后很快出现复发进展,因此,自20世纪80年代起已开展不少小细胞肺癌维持治疗的相关临床研究,涉及到化疗药物、生物制剂及分子靶向药物。但其结果仍存在争论,现对该方面内容综述如下。 Lung cancer is one of the common malignant tumors in the world, the incidence of small cell lung cancer is about 15% among them. Small ceU lung cancer is highly sensitive to first-line chemotherapy3 but most of the patients relapse after the first-line therapy quickly. Despitemany clinical researchof chemotherapy, biological agents and molecular targeting agents since the 1980s, there still remains a substantial lack of consensus regarding the appropriate therapeutic management on maintenance therapy of small cell lung cancer. The review focuses on maintenance therapy of small cell lung cancer.
作者 陆云云 范云
出处 《中国肺癌杂志》 CAS CSCD 北大核心 2015年第9期559-564,共6页 Chinese Journal of Lung Cancer
关键词 肺肿瘤 维持治疗 化疗 Lung neoplasms Maintenance therapy Chemotherapy
  • 相关文献

参考文献32

  • 1Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 2006, 24(28): 4539-4544.
  • 2Jackman DM, Johnson BE. Small-cell lung cancer. Lancet, 2005, 366(9494): 1385-1396.
  • 3Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 1979, 63(11-12): 1727-1733.
  • 4Cullen M, Morgan D, Gregory W, et al. Maintenance chemotherapy for anaplastic small cell carcinoma of the bronchus: a randomised, controlled trial. Cancer Chemother Pharmacol, 1986, 17(2): 157-160.
  • 5Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.J Clin Oncol, 1993, 11(7): 1230-1240.
  • 6Einhorn LH, Crawford J, Birch R, et al. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicinj and vincristine in limited small-cell lung cancer.J Clin Oncol, 1988, 6(3): 451-456.
  • 7Johnson DH, Bass D, Einhorn LH, et aLCombination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. J Clin Oncol, 1993, 11(7): 1223-1229.
  • 8Sculier JP, Paesmans M, Bureau G, et al. Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.J Clin Oncol, 1996,14(8): 233%2344.
  • 9Hanna NH, Sandier AB, Loehrer PJ Sr, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol, 2002, 13(1): 95-102.
  • 10Schiller JH, Adak S, Celia D, et al. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593-a phase III trial of the Eastern Cooperative Oncology Group. JClin Oncol, 2001, 19(8): 2114-2122.

二级参考文献10

  • 1Ihde DC. Chemotherapy of lung cancer. N EnglJ Med, 1992, 327(20): 1434-1441.
  • 2Clark R, Ihde DC. Small cell lung cancer: treatment progress and prospects. Oncology (Williston Park), 1998, 12(5): 647-658.
  • 3Johnson BE, Janne PA. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am, 2004, 18(2): 309-322.
  • 4Johnson DH. Treatment of relapsed small cell lung cancer. Lung Cancer, 1994, 11(Suppl 1): 142-143.
  • 5Spira A, Ettinger DS. Drug therapy: multidisciplinary management of lung cancer. N EnglJ Med, 2004, 350(4): 379-392.
  • 6Bozcuk H, Artac M, Ozdogan M, et al. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC) ? A meta-analysis of the published controlled trials. Cancer, 2005, 104(12): 2650-2657.
  • 7Von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophos- phamide, doxorubicin, and vincristine for the treatment of recurrent small- cell lung cancer.J Clin Oncol, 1999, 17(2): 658-667.
  • 8Schiller JH, Adak S, Celia D, et al. Topotecan versus observation after cispla- tin plus etoposide in extensive-stage small cell lung cancer: E7593-a phase III trial of the eastern cooperative oncology group. J Clin Oncol, 2001, 19(8): 2114-2122.
  • 9Bonner J, Kozelsky T. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol, 1996, 39(1-2): 109-112.
  • 10Eckardt JR, yon Pawel Jr Papai Z, et al. Opcn-labcl, multicenter, randomizcdj phase III study comparing oral topotecan/cisplatin versus etoposide/cis- platin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol, 2006, 24(13): 2044-2051.

共引文献11

同被引文献84

引证文献10

二级引证文献65

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部